Author : Naina mohamed pakkir maideen
Keyword : Drug interactions, dihydropyridine calcium channel blockers, cyp3a4 enzymes, nifedipine, amlodipine, felodipine.
Subject : Pharmacology
Article Type : Review article
DOI : 10.13187/ejm.2019.2.106
Article QR Code
Article File : Full Text PDF
Abstract : Dihydropyridine Calcium Channel Blockers (CCBs) are widely used as first-line agents to treat hypertension in black patients and in patients aged more than 55 years. They have been identified as the substrates of intestinal and hepatic CYP3A4 enzymes and this review focuses on possible drug-drug interactions of dihydropyridine CCBs involving CYP3A4 enzymes. As object drugs, the dihydropyridine CCBs involved in drug-drug interactions with drugs such as Macrolide antibiotics, Azole antifungals, Protease inhibitors and fruit juices like Grapefruit juice and Seville orange juice and increase the plasma concentrations of dihydropyridine CCBs resulting in enhanced adverse effects. In addition, the drugs like Rifampicin, Phenytoin, and other antiepileptics including Carbamazepine and Phenobarbital decrease the bioavailability of dihydropyridine CCBs. Moreover, as precipitant drugs dihydropyridine CCBs increase the plasma concentrations of Statins and Cyclosporine and decrease the therapeutic efficacy of Clopidogrel. The prescribers and pharmacists are required to be aware of the adverse drug interactions of dihydropyridine CCBs to prevent adverse outcomes.
Article by : Naina Mohamed Pakkir Maideen
Article add date : 2021-12-21
How to cite : Naina mohamed pakkir maideen. (2021-December-21). Drug interactions of dihydropyridine calcium channel blockers (ccbs) involving cyp3a4 enzymes. retrieved from https://www.openacessjournal.com/abstract/945